NCT00290342View on ClinicalTrials.gov

Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

458

Participants

Timeline

Start Date

January 1, 2006

Primary Completion Date

January 1, 2007

Study Completion Date

January 23, 2007

Conditions
TetanusAcellular PertussisDiphtheria
Interventions
BIOLOGICAL

DTPa-IPV

3 intramuscular injections

BIOLOGICAL

DTPa

3 intramuscular injections

BIOLOGICAL

IMOVAX Polio®

3 intramuscular injections

Trial Locations (9)

420-767

GSK Investigational Site, Bucheon-si

700-712

GSK Investigational Site, Daegu

Unknown

GSK Investigational Site, Gwangju

GSK Investigational Site, Seoul

400-711

GSK Investigational Site, Incheon

561-712

GSK Investigational Site, Jeonju

130-702

GSK Investigational Site, Seoul

139-707

GSK Investigational Site, Seoul

150-719

GSK Investigational Site, Seoul

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY